Analysis of a model for hepatitis C virus transmission that includes the
  effects of vaccination with waning immunity by Tahir, Daniah et al.
ar
X
iv
:1
71
2.
08
54
8v
1 
 [q
-b
io.
PE
]  
22
 D
ec
 20
17
Analysis of a model for hepatitis C virus transmission that
includes the effects of vaccination with waning immunity
Daniah Tahir1,2∗, Abid Ali Lashari2,3, and Kazeem Oare Okosun4
1Uppsala University, 75106, Uppsala, Sweden
2National University of Sciences and Technology, H-12, Islamabad, Pakistan
3Stockholm University, 10691, Stockholm, Sweden
4Vaal University of Technology, Private Bag X021, Vanderbijlpark, South Africa
∗Correspondence to be sent to: Department of Mathematics, Uppsala University, 75106,
Uppsala, Sweden. E-mail: daniah.tahir@math.uu.se
Abstract
This paper considers a mathematical model based on the transmission dy-
namics of hepatitis C virus (HCV) infection. In addition to the usual com-
partments for susceptible, exposed, and infected individuals, this model includes
compartments for individuals who are under treatment and those who have had
vaccination against HCV infection. It is assumed that the immunity provided
by the vaccine fades with time. The basic reproduction number, R0, and the
equilibrium solutions of the model are determined. The model exhibits the
phenomenon of backward bifurcation where a stable disease-free equilibrium co-
exists with a stable endemic equilibrium whenever R0 is less than unity. It is
shown that the use of only a perfect vaccine can eliminate backward bifurcation
completely. Furthermore, a unique endemic equilibrium of the model is proved
to be globally asymptotically stable under certain restrictions on the parameter
values. Numerical simulation results are given to support the theoretical pre-
dictions. [epidemiological model; equilibrium solutions; backward bifurcation;
global asymptotic stability; Lyapunov function.]
1 Introduction
The liver of a hepatitis patient is one of the most frequently damaged organs in the
body, and it is indeed fortunate that it has a very large functional reserve. In the
experimental animal, it has been shown that only 10% of the hepatic parenchyma
(the functional part of the liver) is required to maintain normal liver function (Cotran
et al. 1994). The liver can be infected due to a variety of infectious agents such as
parasites, viruses, and bacteria, and diseases of the liver have a variety of causes such
as obstructive, vascular, metabolic and toxic involvements.
Hepatitis C is the inflammation of the liver caused by hepatitis C virus (HCV), and
spreads through contact with contaminated blood. Hepatitis C may be an acute
infection, which spans over a period of weeks to a few months, or chronic infection,
in which the virus persists for a longer time (Di Bisceglie 2000; Das et al. 2005).
Acute hepatitis is characterized by moderate liver injury and if symptoms appear,
they include fatigue, loss of appetite, abdominal pain, fever and jaundice. However,
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most of the times, acute hepatitis is asymptomatic. A large percentage of patients
with HCV infection recover completely, but some develop long term chronic hepati-
tis or massive necrosis of the liver. Chronic HCV infection may damage the liver
permanently, cause cirrhosis, hepatic failure, and sometimes liver cancer.
Today, HCV infects an estimated 170 million people worldwide (Qesmi et al. 2010).
Around 150 million people are chronically infected with HCV. HCV infection is a
major cause of death of more than 350,000 people every year. Countries with the
highest prevalence of chronic liver infection are Egypt (15%), Pakistan (4.8%) and
China (3.2%) (Lozano 1990). Although, treatment for this infection does exist, the
current drug therapies are ineffective in completely eliminating the virus and patients
suffering from chronic illness may require a liver transplant (Qesmi et al. 2010).
Unfortunately, there is no effective vaccine yet developed that may help prevent the
spread of the disease. At present, various attempts are being made to create such
a vaccine (Chen and Li 2006). Thus, it is crucial to assess the potential impact of
HCV vaccine on the population.
Some mathematical models on HCV infection have been formulated recently, but
much work has not been done, since it is a relatively new disease (discovered in
1989) and data is not available on account of the high variability of the HCV. In
contrast, more research has been carried out on hepatitis B virus (HBV) infection.
Several epidemiological models have focused on the effects of preventive measures
as well as control of HBV infection (Zhang and Zhou 2012). This has helped in
creating cost effective disease prevention techniques. The modes of transmission of
both HCV and HBV are same, i.e. through blood, thus mathematical models on
both infections are somewhat inter related. Some mathematical models were formed
on HCV infection that considered infected cells, uninfected cells and viral cells in
the human host. The basic aim of these models was to study the effects of liver
transplant in patients with HCV infection. But in major cases, HCV infection is not
completely eliminated even after the transplant. Thus, these models were extended to
include more infected compartments (Dahari et al. 2005). Martcheva and Castillo-
Chavez (2003) introduced an epidemiologic model of HCV infection with chronic
infectious stage in a varying population. Their model does not include a recovered or
immune class and it falls within the susceptible-infected- susceptible (SIS) category of
models. A susceptible-infected-recovered (SIR) model was used by Jager et al. (2004)
to study the transmission of HCV among injecting drug users, while susceptible-
infected-removed-susceptible (SIRS) type models that allow waning immunity are
presented in Zeiler et al. (2010). Also, a deterministic model for HCV transmission
is used by Elbasha (2013), with the objective of assessing the impact of therapy on
public health.
Our aim is to meticulously analyze the model and examine various parameters to
explore their effect on the transmission of HCV and its control. The model focuses
on studying the effects of imperfect vaccines on the control of hepatitis C. The model
shows that an imperfect vaccine reduces the number of individuals who are exposed
to HCV, while a perfect vaccine completely removes them. We have subdivided the
total population into six mutually-exclusive compartments of susceptible, exposed,
acutely infected, chronically infected, treated and vaccinated individuals. Ordinary
differential equations are used to model the HCV infection. This model can help pro-
vide insights into the spread of HCV infection and the assessment of the effectiveness
of immunization techniques.
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This paper is organized as follows: The mathematical model is developed and an-
alyzed in Section 2. The stability of the disease free equilibrium, and the endemic
equilibrium is discussed, along with the effects of vaccination on backward bifurcation
phenomenon. Numerical simulations are also provided in the same section. Section
3 summarizes the final results of the paper.
2 Model Formulation
The total population at time t, denoted by N(t), is divided into sub-populations of
susceptible individuals, S(t), exposed individuals with hepatitis C symptoms, E(t),
individuals with acute infection, I(t), individuals undergoing treatment, T (t), indi-
viduals with chronic infection, Ch(t), and vaccinated individuals, V (t), so that
N(t) = S(t) + E(t) + I(t) + T (t) + Ch(t) + V (t).
It is assumed that the mode of transmission of HCV infection is horizontal. We
further assume that mixing of individual hosts is homogeneous (every person in the
population N(t) has an equal chance of getting HCV infection). The following system
of ordinary differential equations describes the dynamics of the HCV infection
dS
dt
= (1− b)Λ + ρT + αV − (β1I + β2Ch + β3T )S + σCh − µS,
dE
dt
= (β1I + β2Ch + β3T )S + (1− ψ)(β1I + β2Ch + β3T )V − (ǫ+ µ)E,
dI
dt
= ǫE − (κ+ µ)I,
dT
dt
= π1κI + π2Ch − (ρ+ µ)T,
dCh
dt
= (1− π1)κI − (π2 + σ + µ)Ch,
dV
dt
= bΛ− (α+ µ)V − (1− ψ)(β1I + β2Ch + β3T )V.
(2.1)
The recruitment rate of susceptible humans is Λ. A proportion, b, of these susceptible
individuals is vaccinated. The death rate of individuals is denoted by µ. The rate
of progression from acute infected class to both treated and chronic infected class
is given by κ. The acutely infected proportion of individuals who enter the treated
class is π1. The remaining infected proportion, (1 − π1), progresses to the chronic
infectious stage. The rate of progression for treatment from chronic hepatitis is given
by π2. The term ǫ is the rate of progression from exposed class to acute infected
class. The recovery rates due to treatment and naturally from the chronic group are
ρ and σ, respectively.
The transmission coefficients of HCV infection by individuals with acute hepatitis
C, I(t), chronic hepatitis C, Ch(t) and individuals undergoing treatment but not yet
cured, T (t) are β1, β2, and β3, respectively. Following effective contact with I(t), C(t),
and T (t), susceptible individuals can acquire HCV at a rate (β1I + β2Ch + β3T ). ψ
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Table 1: Description of parameters
Parameter Description
Λ recruitment rate of individuals
µ death rate of individuals
α waning rate of the vaccine
ψ vaccine efficacy
βi transmission rate (i=1, 2, 3)
b proportion of vaccinated individuals
κ rate of progression from the acute state
to treated and chronic state
ǫ rate of transfer from exposed class
to acute infected class
π1 proportion of individuals who enter
the treated class from acutely infected class
π2 rate of progression for treatment
from chronic hepatitis
ρ rate of recovery due to treatment
σ rate of recovery from the chronic class
(0 < ψ ≤ 1) represents the vaccine efficacy, with ψ = 1 representing a perfect
vaccine, and ψ ∈ (0, 1) corresponding to an imperfect vaccine which wanes with time.
The term (1 − ψ) corresponds to the decrease in disease transmission in vaccinated
individuals, in contrast to susceptible individuals who are not vaccinated. Hence,
vaccinated individuals acquire HCV at a reduced rate (1 − ψ)(β1I + β2Ch + β3T ).
The rate at which the vaccine wanes is denoted by α. The parameter description is
described in Table 1.
In the proposed model (2.1), the total population is S + E + I + T + Ch + V =
Λ
µ
for all t ≥ 0, provided that S(0)+E(0) + I(0) + T (0)+Ch(0)+ V (0) =
Λ
µ
. Thus, the
biologically feasible region for system (2.1) given by
∆ = {(S,E, I, T,Ch, V ) ∈ R
6 : S + E + I + T + Ch + V =
Λ
µ
},
is positively invariant with respect to the system (2.1).
2.1 Local stability of the disease-free equilibrium (DFE)
For the mathematical model in equation (2.1), the DFE, P0 is given by
(S0, E0, I0, T0, Ch0, V0) =
((1− b)Λ
µ
+
αbΛ
µ(α+ µ)
, 0, 0, 0, 0,
bΛ
α+ µ
)
.
The local stability of P0 is determined by the next generation operator method
(Driessche and Watmough 2002) on system (2.1). For this purpose, the basic repro-
duction number (the average number of secondary infections produced by an infected
individual in a completely susceptible population), denoted by R0, is obtained. Using
the same notation as in Driessche and Watmough (2002), R0 is given by
R0 =
ǫ
K1K2
(
(1− b)Λ
µ
+
αbΛ
µK5
+(1−ψ)
bΛ
K5
)
[
β1+β2
κ(1− π1)
K4
+β3
(π1κK4 + π2κ(1 − π1))
K3K4
]
,
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where
K1 = ǫ+ µ, K2 = κ+ µ, K3 = ρ+ µ, K4 = π2 + σ + µ,K5 = α+ µ.
Using Theorem 2 in Driessche and Watmough (2002), the following result is estab-
lished.
Theorem 2.1. The DFE of the model (2.1), is locally asymptotically stable if R0 < 1,
and unstable if R0 > 1.
2.2 Endemic equilibria and backward bifurcation
To calculate the endemic equilibrium, we consider the following reduced system of
differential equations
dE
dt
= (β1I + β2Ch + β3T )(
Λ
µ
− E − I − T − Ch − ψV )−K1E,
dI
dt
= ǫE −K2I,
dT
dt
= π1κI + π2Ch −K3T,
dCh
dt
= (1− π1)κI −K4Ch,
dV
dt
= bΛ−K5V − (1− ψ)(β1I + β2Ch + β3T )V.
(2.2)
We will consider the dynamics of the flow generated by (2.2) in the invariant region
Ω = {E + I + T + Ch + V ≤
Λ
µ
}.
The endemic equilibrium for system (2.2) is P ∗(E∗, I∗, T ∗, C∗h, V
∗), where
E∗ =
K2I
∗
ǫ
,
T ∗ =
(π1κK4 + π2(1− π1)κ)I
∗
K4K3
,
C∗h =
(1− π1)κI
∗
K4
,
V ∗ =
bΛ
K5 + (1− ψ)[β1 + β2
κ(1 − π1)
K4
+ β3
(π1κK4 + π2κ(1 − π1))
K3K4
]I∗
,
(2.3)
and I∗ is the root of the following quadratic equation
a1I
∗2 + a2I
∗ + a3 = 0. (2.4)
Here
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Figure 1: Backward Bifurcation diagram, with parameter values β2 = 0.09, β3 = 0.19,
µ = 0.00004, α = 0.1, ρ = 0.152, π1 = 0.001, π2 = 0.02, ǫ = 0.022, κ = 0.032,
Λ = 0.0052, σ = 0.2, ψ = 0.95.
a1 = (1 − ψ)B
2[µK2K3K4 + ǫµ K3K4 + (π1κK4 + π2κ(1− π1)) ǫµ
+ǫκµ(1− π1)K3],
a2 = B[µK2K3K4K5 + ǫµK3K4K5 + ǫµK5(π1κK4 + π2(1− π1)κ)
+(1− π1)ǫκµK3K5 + (1− ψ)µK1K2K3K4 − (1− ψ)ΛǫBK3K4],
a3 = µK1K2K4K3K5(1−R0),
(2.5)
with
B =
[
β1 + β2
κ(1− π1)
K4
+ β3
(π1κK4 + π2κ(1− π1))
K3K4
]
.
The endemic equilibria of the model (2.2) can then be obtained by solving for I∗ from
(2.4), and substituting the positive values of I∗ into the expressions in (2.3). Hence,
S∗ can be determined from Λ
µ
−E∗ − I∗ − T ∗ −C∗h − V
∗. From (2.5), it can be seen
that a1 is always positive (for an imperfect vaccine), and a3 is positive (negative) if
R0 is less than (greater than) unity. Thus, the following result is established
Theorem 2.2. The model in (2.2) has:
(i) a unique endemic equilibrium if a3 < 0⇔ R0 > 1;
(ii) a unique endemic equilibrium if a2 < 0, and a3 = 0 or a
2
2 − 4a1a3 = 0;
(iii) two endemic equilibria if a3 > 0, a2 < 0 and a
2
2 − 4a1a3 > 0;
(iv) no endemic equilibrium otherwise.
Hence, the model has a unique endemic equilibrium (P ∗) whenever R0 > 1, as evident
from case (i) of the above theorem. Also, case (iii) indicates a possible chance of
backward bifurcation (where a locally asymptotically stable DFE exists along with a
locally asymptotically stable endemic equilibrium when R0 < 1). Since, for a3 > 0,
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R0 < 1, the model will have a disease-free equilibrium and two endemic equilibria.
To check for this, the discriminant a22 − 4a1a3 is set to zero and is solved for the
critical value of R0. The critical value is denoted by Rc and is given by
Rc = 1−
a22
4a1µK1K2K5K3K4
.
Backward bifurcation occurs for those values of R0 which satisfy Rc < R0 < 1.
This is illustrated by simulating the model with these parameter values: β1 = 0.03,
β3 = 0.19, µ = 0.00004, α = 0.1, ρ = 0.152, π1 = 0.001, π2 = 0.02, ǫ = 0.022,
κ = 0.032, Λ = 0.0052, σ = 0.2, ψ = 0.95. (These values are used merely for
illustration purposes, and may not be realistic from epidemiological point of view.)
The result is shown in Fig. 1. It can be seen that a locally asymptotically stable
disease free equilibrium, a locally asymptotically stable endemic equilibrium, and, an
unstable endemic equilibrium coexist when R0 < 1.
2.2.1 Proof of backward bifurcation phenomenon
The phenomenon of backward bifurcation can be proved by using the center manifold
theory on system (2.1). A theorem given by Castillo-Chavez and Song (2004) will be
used here. To apply this method, the following change of variables is made on the
model:
x1 = S, x2 = E, x3 = I, x4 = T, x5 = Ch, x6 = V.
Let
X = (x1, x2, x3, x4, x5, x6)
T .
Thus, the system (2.1) can now be written as dX
dt
= (f1, f2, f3, f4, f5, f5, f6)
T and is
given below
dx1
dt
= f1 = (1− b)Λ + ρx4 + αx6 − (β1x3 + β2x5 + β3x4)x1 + σx5 − µx1,
dx2
dt
= f2 = (β1x3 + β2x5 + β3x4)x1 + (1− ψ)(β1x3 + β2x5 + β3x4)x6 −K1x2,
dx3
dt
= f3 = ǫx2 −K2x3,
dx4
dt
= f4 = π1κx3 + π2x5 −K3x4,
dx5
dt
= f5 = (1− π1)κx3 −K4x5,
dx6
dt
= f6 = bΛ−K5x6 − (1− ψ)(β1x3 + β2x5 + β3x4)x6.
(2.6)
Choose β1 as the bifurcation parameter, and let R0 = 1. Solving for β1 = β¯1 from
R0 = 1 gives
β1 = β¯1 =
K1K2
ǫA
−
β2(1− π1)κ
K4
−
β3(π1κK4 + π2(1− π1)κ)
K3K4
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where
A =
(1− b)Λ
µ
+
αbΛ
µK5
+ (1− ψ)
bΛ
K5
.
The Jacobian matrix (J) of system (2.6) calculated at P0, with β1 = β¯1, is given as
follows
J =


−µ 0 −β1Kh ρ− β3Kh σ − β2Kh α
0 −K1 β1A β3A β2A 0
0 ǫ −K2 0 0 0
0 0 π1κ −K3 π2 0
0 0 (1− π1)κ 0 −K4 0
0 0 −β1Km −β3Km −β2Km −K5


,
where
Kh = (
Λ
µ
−
bΛ
K5
),Km =
(1− ψ)Λb
K5
.
The characteristic equation (in λ) of J is given as
(−µ− λ)(−K5 − λ)
(
λ4 +D1λ
3 +D2λ
2 +D3λ+D4
)
= 0, (2.7)
where
D1 = K1 +K2 +K3 +K4,
D2 = K3K4 +K1K3 +K2K3 +K1K4 +K2K4 +K1K2 − β1ǫA,
D3 = K1K3K4 +K2K3K4 +K1K2K3 +K1K2K4 − β1ǫA(K3 +K4)
−β3κπ1ǫA− (1− π1)β2κǫA,
D4 = K1K2K3K4(1−R0).
For R0 = 1, the characteristic equation (2.7) becomes
λ(−µ− λ)(−K5 − λ)
(
λ3 +D1λ
2 +D2λ+D3
)
= 0. (2.8)
Equation (2.8) has a zero eigenvalue and two negative eigenvalues, −µ and −K5. The
remaining three eigenvalues are given by the following cubic equation in λ
λ3 +D1λ
2 +D2λ+D3 = 0. (2.9)
D1 is clearly positive. D2 and D3 can easily be shown to be positive when β1 is
replaced with β¯1. Similarly, D1D2 − D3 > 0. Hence, using the Routh-Hurwitz
criterion (Allen 2007), all roots of the characteristic equation (2.9) have negative
real parts. Therefore, the Jacobian matrix of the linearized system has a simple
zero eigenvalue, with all other eigenvalues having negative real parts. Hence, the
Center Manifold Theory (Castillo-Chavez and Song 2004) can be used to analyze the
dynamics of system (2.6).
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Corresponding to the zero eigenvalue, the Jacobian matrix J |β1=β¯1 can be shown to
have a right eigenvector given by w = (w1, w2, w3, w4, w5, w6)
T , where
w1 =
1
µ
(
ρ(
π1κK4 + π2(1− π1)κ
K3K4
) + σ
(1− π1)κ
K4
−
K1K2
ǫA
(
(1 − b)Λ
µ
+
αbΛ
µK5
+
α(1− ψ)bΛ
K25
)
)
w3,
w2 =
K2
ǫ
w3,
w3 = w3,
w4 =
π1κ
K3
w3 +
π2(1− π1)κ
K3K4
w3,
w5 =
(1− π1)κ
K4
w3,
w6 =
−(1− ψ)bΛK1K2
K25ǫA
w3.
Similarly, corresponding to the zero eigenvalue, J |β1=β¯1 has a left eigenvector given
by v = (v1, v2, v3, v4, v5, v6), where
v1 = 0,
v2 =
ǫ
K1
v3,
v3 = v3,
v4 =
ǫβ3A
K1K3
v3,
v5 =
ǫβ2A
K1K4
v3 +
ǫβ3π2A
K1K4K3
v3,
v6 = 0.
Calculation of a. For system (2.6), the corresponding non-zero partial derivatives
of fi (i = 1, 2, ..., 6) calculated at the DFE, P0, are given by
∂2f1
∂x1∂x3
= −β1,
∂2f1
∂x1∂x5
= −β2,
∂2f1
∂x1∂x4
= −β3,
∂2f2
∂x1∂x3
= β1,
∂2f2
∂x1∂x5
= β2,
∂2f2
∂x1∂x4
= β3,
∂2f2
∂x3∂x6
= (1− ψ)β1,
∂2f2
∂x5∂x6
= (1− ψ)β2,
∂2f2
∂x4∂x6
= (1− ψ)β3,
∂2f6
∂x3∂x6
= −(1− ψ)β1,
∂2f6
∂x3∂x6
= −(1− ψ)β2,
∂2f6
∂x4∂x6
= −(1− ψ)β3.
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Consequently, the associated bifurcation coefficient, a, is given by
a =
6∑
k,i,j=1
ukwiwj
∂2fk
∂yi∂yj
(0, 0)
=
ǫu3w
2
3
K1µ
(
β1 + β2
κ(1− π1)
K4
+ β3
(π1κK4 + π2κ(1− π1))
K3K4
)[
ρ
(
π1κK4 + π2(1− π1)κ
K3K4
)
+σ
(1− π1)κ
K4
−
K1K2
ǫA
(
(1− b)Λ
µ
+
αbΛ
µK5
+
α(1− ψ)bΛ
K25
)
−
(1− ψ)2µbΛK1K2
K25ǫA
]
.
Calculation of b. The required partial derivative, for the computation of b, is
calculated at P0, and is given by
∂2f2
∂x3∂β1
= A. Hence, the associated bifurcation
coefficient, b, is given as
b =
6∑
k,i=1
ukwi
∂2fk
∂xi∂φ
(0, 0) =
Aǫu3w3
K1
> 0.
Since the coefficient b is always positive, it follows from Theorem 3.3 given by Castillo-
Chavez and Song B (2004) that the system (2.2) will undergo backward bifurcation
if the coefficient a is positive.
The phenomenon of backward bifurcation poses a lot of problems, since it jeopar-
dizes the possibility of total disease eradication from the population, when the basic
reproduction number is less than unity. Hence, it is instructive to try to eliminate
the backward bifurcation effect. Since, this effect requires the existence of at least
two endemic equilibria when R0 < 1 (Garba et al. 2008; Safi and Gumel 2011), it
may be removed by considering such a model in which positive endemic equilibria
cease to exist.
2.2.2 Use of a perfect vaccine to eliminate backward bifurcation
The backward bifurcation behavior of the proposed HCV infection model (2.1), can
be eliminated by using a perfect vaccine, i.e., when ψ=1. For ψ=1, the original model
now becomes
dS
dt
= (1− b)Λ + ρT + αV − (β1I + β2Ch + β3T )S + σCh − µS,
dE
dt
= (β1I + β2Ch + β3T )S −K1E,
dI
dt
= ǫE −K2I,
dT
dt
= π1κI + π2Ch −K3T,
dCh
dt
= (1− π1)κI −K4Ch,
dV
dt
= bΛ−K5V.
(2.10)
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Table 2: Values of parameters
Parameter Value(range) Units Source
Λ 85 per year (Martin et al. 2011; Martin et al. 2011)
µ 0.085 per year (Martin et al. 2011; Martin et al. 2011)
βi (0,1) per year (Martin et al. 2011; Martin et al. 2011)
π1 0.26 - (Martin et al. 2011; Martin et al. 2011)
ρ 1.992 per year (Martin et al. 2011)
ψ (0,1] - Variable
α 0.006 - Assumed
b 0.4 - Assumed
κ 2.085 - Assumed
ǫ 0.569 - Assumed
π2 0.25 - Assumed
σ 0.004 - Assumed
System (2.10) has a DFE, P0(S0, 0, 0, 0, 0, V0), which is the same as the original model
given in equation (2.1). The corresponding vaccinated reproduction number, R¯0, for
model (2.10) is given as
R¯0 = R0 |ψ=1=
ǫ
K1K2
(
(1− b)Λ
µ
+
αbΛ
µK5
)(
β1+β2
κ(1 − π1)
K4
+β3
(π1κK4 + π2κ(1− π1))
K3K4
)
.
Consider now, the quadratic equation (2.4), rewritten below for convenience
a1I
∗2 + a2I
∗ + a3 = 0.
For ψ = 1, using the values given in equation (2.5), the coefficients a1, a2, and a3
of the above quadratic equation reduce to a1 = 0, a2 > 0, and a3 ≥ 0 (whenever
R¯0 = R0 |ψ=1≤ 1). In this case, the quadratic equation (2.4) will have just a single
non positive solution
I∗ = −
a3
a2
≤ 0.
Hence, whenever R¯0 ≤ 1, the model (2.10) has no positive endemic equilibrium.
This clearly suggests the impossibility of backward bifurcation (because for backward
bifurcation to occur, there must exist at least two endemic equilibria whenever R¯0 ≤
1).
A contour plot of vaccinated reproduction number (R¯0) as a function of proportion
of vaccinated humans (b) and vaccine efficacy (ψ) is shown in Fig. 2. The parameter
values used to generate this diagram are given in Table 2. The contours illustrate
a significant decrease in the vaccinated reproduction number, R¯0, with increasing
vaccine efficacy, ψ, and proportion of vaccinated humans, b. It can be seen that
very high vaccine efficacy and vaccine coverage is required to control HCV infection
effectively in the population. Almost all of the susceptible individuals should have
had vaccination, and vaccine efficacy must be 100% for R¯0 to be less than one, so
that the spread of HCV infection is controlled effectively.
The global stability of the disease free equilibrium can be proved in the region ∆ as
follows.
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Figure 2: Simulation of the model (2.10), showing a contour plot of R¯0 as a function
of proportion of vaccinated humans (b) and vaccine efficacy (ψ).
Theorem 2.3. For a perfect vaccine (ψ = 1), P0 is globally asymptotically stable in
∆ whenever
R¯0 ≤
S0µ
Λ
< 1,
where
S0 =
(1− b)Λ
µ
+
αbΛ
µ(α+ µ)
.
Proof : Let
V = A1E +A2I +A3T +A4Ch,
where
A1 =
S0µ
Λ
, A2 =
S0K1µ
ǫΛ
, A3 =
β3S0
K3
, A4 =
β2S0
K4
+
β3S0π2
K3K4
.
Then,
V ′ = A1E
′ +A2I
′ +A3T
′ +A4C
′
h
= A1
[
(β1I + β2Ch + β3T )S −K1E
]
+A2
[
ǫE −K2I
]
+A3
[
π1κI + π2Ch −K3T
]
+A4
[
(1− π1)κI −K4Ch
]
.
Since, S + E + I + T + Ch + V ≤
Λ
µ
, we have that
S ≤
Λ
µ
.
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Therefore V ′ becomes
V ′ ≤ A1
[
(β1I + β2Ch + β3T )
Λ
µ
−K1E
]
+A2
[
ǫE −K2I
]
+A3
[
π1κI + π2Ch −K3T
]
+A4
[
(1− π1)κI −K4Ch
]
= E
[
−K1A1 + ǫA2
]
+ I
[
β1A1
Λ
µ
−K2A2 + π1κA3 +A4κ(1 − π1)
]
+ T
[
β3A1
Λ
µ
−K3A3
]
+ Ch
[
β2A1
Λ
µ
+ π2A3 −K4A4
]
= I
[
S0
(
β1 + β2
κ(1− π1)
K4
+ β3
(π1κK4 + π2κ(1− π1))
K3K4
)
−
S0K2K1µ
ǫΛ
]
=
IK1K2
ǫ
[
R¯0 −
S0µ
Λ
]
≤ 0,
whenever
R¯0 ≤
S0µ
Λ
< 1.
Hence, V ′ ≤ 0 for R¯0 ≤
S0µ
Λ
. It should also be noted that
S0µ
Λ
=
Λ
µ
− bΛ
α+µ
Λ
µ
< 1.
V ′ = 0 whenever E = 0, I = 0, T = 0, Ch = 0, which corresponds to the set
{(E, I, T,Ch) : E = I = T = Ch = 0}. In this set, system (2.10) is given as
dS
dt
= (1− b)Λ + αV − µS,
dE
dt
=
dI
dt
=
dT
dt
=
dCh
dt
= 0,
dV
dt
= bΛ− (α+ µ)V.
(2.11)
When t→∞, the solution of system (2.11) becomes
S =
(1− b)Λ
µ
+
αbΛ
µ(α+ µ)
, E = 0, I = 0, T = 0, Ch = 0, V =
bΛ
α+ µ
.
Clearly, when t→∞, the solution to system (2.11) approaches the DFE, P0(S0, 0, 0, 0, 0, V0).
By using LaSalle’s invariance principle (LaSalle 1976), P0 is found to be globally
asymptotically stable in ∆. This result is illustrated by simulating the model (2.10)
using a reasonable set of parameter values given in Table 2. The plot in Fig. 3 shows
that the disease is eliminated from the population.
2.3 Global stability of the endemic equilibrium
Theorem 2.4. The endemic equilibrium P ∗(S∗, E∗, I∗, T ∗, C∗h, V
∗) of the system
(2.1), with ρ = 0 and σ = 0, is globally asymptotically stable whenever it exists.
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Figure 3: Simulated in MATLAB, these figures from (a) to (f) are a simulation of
system (2.10), showing the total number of susceptible, exposed, acutely infected,
chronically infected, treated and vaccinated individuals, respectively, as a function of
time (years). Parameter values are given in Table 2, with ψ = 1 for perfect vaccine,
β1 = 0.0009, β2 = 0.0006, β3 = 0.0001 and R¯0 = 0.654 < 1. The numerical simulation
shows that the disease is eliminated when R¯0 < 1 . It is assumed that the acute phase
is more infectious than the chronic stage which is in turn more infectious than the
treatment phase. So β1 > β2 > β3.
In order to prove the above theorem, we have used the method given by Li et al.
(2012, 2011). At the endemic equilibrium P ∗, with ρ = 0 and σ = 0, the following
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equations are satisfied:
0 = (1− b)Λ + αV ∗ − (β1I
∗ + β2C
∗
h + β3T
∗)S∗ − µS∗
0 = (β1I
∗ + β2C
∗
h + β3T
∗)S∗ + (1− ψ)(β1I
∗ + β2C
∗
h + β3T
∗)V ∗ − (ǫ+ µ)E∗
0 = ǫE∗ − (κ+ µ)I∗
0 = π1κI
∗ + π2C
∗
h − µT
∗
0 = (1− π1)κI
∗ − (π2 + µ)C
∗
h
0 = bΛ− (α+ µ)V ∗ − (1− ψ)(β1I
∗ + β2C
∗
h + β3T
∗)V ∗.
(2.12)
Let
x1 =
S
S∗
, x2 =
E
E∗
, x3 =
I
I∗
, x4 =
T
T ∗
, x5 =
Ch
C∗h
, x6 =
V
V ∗
. (2.13)
Then (2.1) can be rewritten as
x′1 = x1
[(1− b)Λ
S∗
(
1
x1
− 1
)
+
αV ∗
S∗
(
x6
x1
− 1
)
− β1I
∗(x3 − 1)− β2C
∗
h(x5 − 1)
−β3T
∗(x4 − 1)
]
,
x′2 = x2
[β1I∗S∗
E∗
(
x3x1
x2
− 1
)
+
β2C
∗
hS
∗
E∗
(
x1x5
x2
− 1
)
+
β3T
∗S∗
E∗
(
x1x4
x2
− 1
)
+(1− ψ)
β1I
∗V ∗
E∗
(
x3x6
x2
− 1
)
+ (1− ψ)
β2C
∗
hV
∗
E∗
(
x5x6
x2
− 1
)
+ (1− ψ)
β3T
∗V ∗
E∗
(
x4x6
x2
− 1
)]
,
x′3 = x3
[ǫE∗
I∗
(
x2
x3
− 1
)]
,
x′4 = x4
[π1κI∗
T ∗
(
x3
x4
− 1
)
+
π2C
∗
h
T ∗
(
x5
x4
− 1
)]
,
x′5 = x5
[
(1− π1)
κI∗
C∗h
(x3
x5
− 1
)]
,
x′6 = x6
[ bΛ
V ∗
( 1
x6
− 1
)
− (1− ψ)β1I
∗(x3 − 1)− (1− ψ)β2C
∗
h(x5 − 1)− (1− ψ)
β3T
∗(x4 − 1)
]
.
(2.14)
The endemic equilibrium P ∗(S∗, E∗, I∗, T ∗, C∗h, V
∗) corresponds to the positive equi-
librium P¯ ∗(1, 1, 1, 1, 1, 1) of (2.14). Since, the global stability of P¯ ∗ is the same as
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that of P ∗, the global stability of P¯ ∗ is described below instead of P ∗. We define the
Lyapunov function as follows
L = a1S
∗(x1 − 1− lnx1) + a2E
∗(x2 − 1− lnx2) + a3I
∗(x3 − 1− lnx3)
+a4T
∗(x4 − 1− lnx4) + a5C
∗
h(x5 − 1− lnx5) + a6V
∗(x6 − 1− lnx6),
where a1, a2, a3, a4, a5 and a6 are positive numbers which are to be determined. Using
(2.12), the time derivative of L along the solutions of system (2.1) is given as
dL
dt
= a1
(
2(1− b)Λ + αV ∗ − β1I
∗S∗ − β2C
∗
h
S∗ − β3T
∗S∗
)
+ a2
(
β1I
∗S∗
+β2C
∗
h
S∗ + β3T
∗S∗ + (1 − ψ)β1I
∗V ∗ + (1− ψ)β2C
∗
h
V ∗ + (1− ψ)
β3T
∗V ∗
)
+ a3ǫE
∗ + a4π1κI
∗ + a5(1− π1)κI
∗ + a6
(
2bΛ− (1− ψ)
β1I
∗V ∗ − (1− ψ)β2C
∗
h
V ∗ − (1− ψ)β3T
∗V ∗
)
− x1
(
a1(1− b)Λ
+a1αV
∗ − a1β1I
∗S∗ − a1β2C
∗
h
S∗ − a1β3T
∗S∗
)
+ x2
(
− a2β1I
∗S∗
−a2β2C
∗
h
S∗ − a2β3T
∗S∗ − a2(1− ψ)β1I
∗V ∗ − a2(1 − ψ)β2C
∗
h
S∗
−a2(1− ψ)β3T
∗V ∗ + a3ǫE
∗
)
+ x3
(
a1β1I
∗S∗ − a3ǫE
∗ + a4π1κI
∗
+a5(1− π1κI
∗ + a6(1− ψ)β1I
∗V ∗)
)
+ x4
(
a1β3T
∗S∗ − a4π1κI
∗
−a4π2C
∗
h
+ a6(1 − ψ)β3T
∗V ∗
)
+ x5
(
a1β2C
∗
h
S∗ + a4π2C
∗
h
− a5(1
−π1)κI
∗ + a6(1− ψ)β2C
∗
h
V ∗
)
− x6
(
− a1αV
∗ + a6bΛ− a6(1− ψ)
β1I
∗V ∗ − a6(1− ψ)β2C
∗
h
V ∗ − a6(1− ψ)β3T
∗V ∗
)
+ x5x6
(
a2(1− ψ)
β2C
∗
h
V ∗ − a6(1 − ψ)β2C
∗
h
V ∗
)
+ x1x3
(
− a1β1I
∗S∗ + a2β1I
∗S∗
)
+x1x5
(
− a1β2C
∗
h
S∗ + a2β2C
∗
h
S∗
)
+ x1x4
(
− a1β3T
∗S∗ + a2β3T
∗S∗
)
+x3x6
(
a2(1− ψ)β1I
∗V ∗ − a6(1− ψ)β1I
∗V ∗
)
+ x4x6
(
a2(1− ψ)β3T
∗V ∗
−a6(1− ψ)β3T
∗V ∗
)
+
1
x1
(
− a1(1− b)Λ
)
+
1
x6
(
− a6bΛ
)
+
x6
x1
(
− a1α
V ∗
)
+
x3
x5
(
− a5(1− π1κI
∗)
)
+
x5
x4
(
− a4π2C
∗
h
)
+
x3
x4
(
− a4π1κI
∗
)
+
x2
x3
(
− a3ǫE
∗
)
+
x3x6
x2
(
− a2(1− π)β1I
∗V ∗
)
+
x3x1
x2
(
− a2β1I
∗S∗
)
+
x5x1
x2
(
− a2β2C
∗
h
S∗
)
+
x1x4
x2
(
− a2β3T
∗S∗
)
+
x4x6
x2
(
− a2(1 − π)β3T
∗V ∗
)
+
x5x6
x2
(
− a2(1− π)β2C
∗
h
V ∗
)
=: F (x1, x2, x3, x4, x5, x6).
We define the function H =
∑14
i=1 Pi, where Pi(i = 1, 2, ..., 14) is given as
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P1 = b1
(
2− x1 −
1
x1
)
,
P2 = b2
(
2− x6 −
1
x6
)
,
P3 = b3
(
3− x1 −
1
x6
−
x6
x1
)
,
P4 = b4
(
3−
1
x1
−
x1x3
x2
−
x2
x3
)
,
P5 = b5
(
4−
1
x1
−
x1x4
x2
−
x3
x4
−
x2
x3
)
,
P6 = b6
(
4−
1
x1
−
x1x5
x2
−
x3
x5
−
x2
x3
)
,
P7 = b7
(
5−
1
x1
−
x1x4
x2
−
x5
x4
−
x2
x3
−
x3
x5
)
,
P8 = b8
(
3−
1
x6
−
x3x6
x2
−
x2
x3
)
,
P9 = b9
(
4−
1
x6
−
x4x6
x2
−
x3
x4
−
x2
x3
)
,
P10 = b10
(
5−
1
x6
−
x4x6
x2
−
x5
x4
−
x2
x3
−
x3
x5
)
,
P11 = b11
(
4−
1
x6
−
x5x6
x2
−
x3
x5
−
x2
x3
)
,
P12 = b12
(
4−
1
x6
−
x1x3
x2
−
x6
x1
−
x2
x3
)
,
P13 = b13
(
5−
1
x6
−
x1x5
x2
−
x6
x1
−
x2
x3
−
x3
x5
)
,
P14 = b14
(
5−
1
x6
−
x1x4
x2
−
x6
x1
−
x2
x3
−
x3
x4
)
.
(2.15)
To determine all the coefficients, ( ai > 0 (i = 1, 2, ..., 6), bi ≥ 0 (i = 1, 2, ..., 14) ) we
let F (x1, x2, x3, x4, x5, x6) = H. Comparing coefficients of F and H, we see that the
terms x2, x4, x5, x5x6, x1x3, x1x5, x1x4, x3x6, and x4x6 of F do not appear in
H. Hence their coefficients will be equal to zero. We solve the resulting equations to
obtain
a1 = a2 = a6 = 1,
a3 =
ǫ+ µ
ǫ
,
a4 =
β3S
∗ + (1− ψ)β3V
∗
µ
,
a5 =
(
S∗ + (1− ψ)V ∗
)(
β2 +
β3pi2
µ
)
π2 + µ
.
Substituting these values into L′ = F (x1, x2, x3, x4, x5, x6), and using equations (2.12)
17
gives
F (x1, x2, x3, x4, x5, x6) =
(
2Λ + αV ∗ + (ǫ+ µ)E∗ + β3
(
S∗ + (1− ψ)V ∗
)
T ∗
+
(
S∗ + (1− ψ)V ∗
)(
β2 +
β3π2
µ
)
C∗h
)
− x1
(
µS∗
)
− x6
(
µV ∗
)
−
1
x1
(
(1− b)Λ
)
−
1
x6
(
bΛ
)
−
x6
x1
(
αV ∗
)
−
x3
x5
((
S∗ + (1− ψ)V ∗
)(
β2 +
β3π2
µ
)
C∗h
)
−
x5
x4
(β3
µ
(
S∗ + (1− ψ)V ∗
)
π2C
∗
h
)
−
x3
x4
(β3
µ
(
S∗ + (1− ψ)V ∗
)
π1κI
∗
)
−
x2
x3
(
(ǫ+ µ)E∗
)
−
x3x6
x2
(
(1− ψ)β1I
∗V ∗
)
−
x1x3
x2
(
β1I
∗S∗
)
−
x1x5
x2
(
β2C
∗
hS
∗
)
−
x1x4
x2
(
β3T
∗S∗
)
−
x4x6
x2
(
(1− ψ)β3T
∗V ∗
)
−
x5x6
x2
(
(1− ψ)β2C
∗
hV
∗
)
.
Comparing the remaining coefficients of F and H gives
b1 = µS
∗ − αV ∗ + b12 + b13 + b14,
b2 = µV
∗ ≥ 0,
b3 = αV
∗ − b12 − b13 − b14,
b4 = β1I
∗S∗ − b12,
b5 = β3T
∗S∗ −
β3
µ
(
S∗ + (1− ψ)V ∗
)
π2C
∗
h + b10 − b14,
b6 = β2C
∗
hS
∗ − b13,
b7 =
β3
µ
(
S∗ + (1− ψ)V ∗
)
π2C
∗
h − b10,
b8 = (1− ψ)β1I
∗V ∗ ≥ 0,
b9 = (1− ψ)β3T
∗V ∗ − b10,
b11 = (1− ψ)β2C
∗
hV
∗ ≥ 0.
(2.16)
To assure that b1, b3, b4, b5, b6, b7 and b9 are non negative, b10, b12, b13, b14 must satisfy
the following inequalities
αV ∗ − µS∗ ≤ b12 + b13 + b14 ≤ αV
∗,
b10 ≤ min
(
(1− ψ)β3T
∗V ∗,
β3
µ
(
S∗ + (1− ψ)V ∗
)
π2C
∗
h
)
,
b14 − b10 ≤ β3T
∗S∗ −
β3
µ
(
S∗ + (1− ψ)V ∗
)
π2C
∗
h,
b12 ≤ β1I
∗S∗, b13 ≤ β2C
∗
hS
∗.
(2.17)
Finally, using equations (2.12), the equality for the constant terms between F (x1, x2, x3, x4, x5, x6)
and H can easily be verified.
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The constrained conditions in (2.17) show that the available values of b10, b12, b13,
and b14 are not unique. Since, b1, b3, b4, b5, b6, b7 and b9 depend on b10, b12, b13, and
b14, their values will also be non unique. Using inequalities in (2.17), we can assign
different values to bi(i = 1, 3, ...14, i 6= 2, 8, 11), and hence H can have different forms
in following three subregions
Case 1: µS > αV,
β3
µ
(
S∗ + (1− ψ)V ∗
)
π2C
∗
h ≤ (1− ψ)β3T
∗V ∗.
For Case 1, using equations (2.16) and (2.17), choose b1 = µS
∗ − αV ∗, b3 = αV
∗,
b4 = β1I
∗S∗, b5 = β3T
∗S∗, b6 = β2C
∗
hS
∗, b7 = 0, b9 = (1−ψ)β3T
∗V ∗−
β3
µ
(
S∗+(1−
ψ)V ∗
)
π2C
∗
h, b10 =
β3
µ
(
S∗ + (1− ψ)V ∗
)
π2C
∗
h, b12 = 0, b13 = 0 and b14 = 0.
Using these values, and the values of b2, b8 and b11, the function F (x1, x2, x3, x4, x5, x6)
becomes
F (x1, x2, x3, x4, x5, x6) =
(µS∗ − αV ∗)
(
2− x1 −
1
x1
)
+ µV ∗
(
2− x6 −
1
x6
)
+ αV ∗
(
3− x1 −
1
x6
−
x6
x1
)
+ β1I
∗S∗
(
3−
1
x1
−
x2
x3
−
x1x3
x2
)
+ β3T
∗S∗
(
4−
1
x1
−
x2
x3
−
x1x4
x2
−
x3
x4
)
+ β2C
∗
hS
∗
(
4−
1
x1
−
x2
x3
−
x1x5
x2
−
x3
x5
)
+ (1− ψ)β1I
∗V ∗
(
3−
1
x6
−
x2
x3
−
x3x6
x2
)
+
(
(1− ψ)β3T
∗V ∗ −
β3
µ
(
S∗ + (1− ψ)V ∗
)
π2C
∗
h
)(
4−
1
x6
−
x2
x3
−
x4x6
x2
−
x3
x4
)
+
β3
µ
(
S∗ + (1− ψ)V ∗
)
π2C
∗
h
(
5−
1
x6
−
x2
x3
−
x4x6
x2
−
x3
x5
−
x5
x4
)
+ (1− ψ)β2C
∗
hV
∗
(
4−
1
x6
−
x2
x3
−
x5x6
x2
−
x3
x5
)
.
Case 2: µS = αV,
β3
µ
(
S∗ + (1− ψ)V ∗
)
π2C
∗
h ≥ (1− ψ)β3T
∗V ∗.
For Case 2, using equations (2.16) and (2.17), choose b1 = 0, b3 = αV
∗, b4 = β1I
∗S∗,
b5 = β3
(
S∗ + (1− ψ)V ∗
)π1κI∗
µ
, b6 = β2C
∗
hS
∗, b7 =
β3
µ
(
S∗ + (1− ψ)V ∗
)
π2C
∗
h − (1−
ψ)β3T
∗V ∗, b9 = 0, b10 = (1− ψ)β3T
∗V ∗, b12 = 0, b13 = 0 and b14 = 0.
Using the above values, and the values of b2, b8 and b11, the function F (x1, x2, x3, x4, x5, x6)
becomes
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F (x1, x2, x3, x4, x5, x6)=
µV ∗
(
2− x6 −
1
x6
)
+ αV ∗
(
3− x1 −
1
x6
−
x6
x1
)
+ β1I
∗S∗
(
3−
1
x1
−
x2
x3
−
x1x3
x2
)
+β3
(
S∗ + (1− ψ)V ∗
)π1κI∗
µ
(
4−
1
x1
−
x2
x3
−
x1x4
x2
−
x3
x4
)
+ β2C
∗
hS
∗
(
4−
1
x1
−
x2
x3
−
x1x5
x2
−
x3
x5
)
+
(β3
µ
(
S∗ + (1− ψ)V ∗
)
π2C
∗
h − (1− ψ)β3T
∗V ∗
)(
5−
1
x1
−
x2
x3
−
x1x4
x2
−
x3
x5
−
x5
x4
)
+ (1− ψ)β1I
∗V ∗
(
3−
1
x6
−
x2
x3
−
x3x6
x2
)
+ (1− ψ)β3T
∗V ∗
(
5−
1
x6
−
x2
x3
−
x4x6
x2
−
x3
x5
−
x5
x4
)
+ (1− ψ)β2C
∗
hV
∗
(
4−
1
x6
−
x2
x3
−
x5x6
x2
−
x3
x5
)
.
Case 3: µS < αV,
β3
µ
(
S∗ + (1− ψ)V ∗
)
π2C
∗
h ≥ (1− ψ)β3T
∗V ∗.
For Case 3, using equations (2.16) and (2.17), we assume that αV ∗ ≤ β3
(
S∗ +
(1 − ψ)V ∗
)π1κI∗
µ
and choose b1 = µS
∗, b3 = 0, b4 = β1I
∗S∗, b5 = β3
(
S∗ + (1 −
ψ)V ∗
)π1κI∗
µ
− αV ∗, b6 = β2C
∗
hS
∗, b7 =
β3
µ
(
S∗ + (1− ψ)V ∗
)
π2C
∗
h − (1− ψ)β3T
∗V ∗,
b9 = 0, b10 = (1− ψ)β3T
∗V ∗, b12 = 0, b13 = 0 and b14 = αV
∗.
Using the above values, and the values of b2, b8 and b11, the function F (x1, x2, x3, x4, x5, x6)
becomes
F (x1, x2, x3, x4, x5, x6)=
µS∗
(
2− x1 −
1
x1
)
+ µV ∗
(
2− x6 −
1
x6
)
+ β1I
∗S∗
(
3−
1
x1
−
x2
x3
−
x1x3
x2
)
+
(
β3
(
S∗ + (1− ψ)V ∗
)π1κI∗
µ
− αV ∗
)(
4−
1
x1
−
x2
x3
−
x1x4
x2
−
x3
x4
)
+ β2C
∗
hS
∗
(
4−
1
x1
−
x2
x3
−
x1x5
x2
−
x3
x5
)
+
β3
µ
(
S∗ + (1− ψ)V ∗
)
π2C
∗
h − (1− ψ)β3T
∗V ∗
(
5−
1
x1
−
x2
x3
−
x1x4
x2
−
x5
x4
−
x3
x5
)
+ (1− ψ)β1I
∗V ∗
(
3−
1
x6
−
x2
x3
−
x3x6
x2
)
+(1− ψ)β3T
∗V ∗
(
5−
1
x6
−
x2
x3
−
x4x6
x2
−
x3
x5
−
x5
x4
)
+ (1− ψ)β2C
∗
hV
∗
(
4−
1
x6
−
x2
x3
−
x5x6
x2
−
x3
x5
)
+ αV ∗
(
5−
1
x6
−
x2
x3
−
x1x4
x2
−
x3
x4
−
x6
x1
)
.
Since, the arithmetic mean is greater than or equal to the geometric mean,
F (x1, x2, x3, x4, x5, x6) ≤ 0 in each of the above three cases. The equality holds only
when x1 = x6 = 1, and x2 = x3 = x4 = x5, i.e. {(x1, x2, x3, x4, x5, x6) ∈ ∆ :
F (x1, x2, x3, x4, x5, x6) = 0} = {(x1, x2, x3, x4, x5, x6) : x1 = x6 = 1, x2 = x3 = x4 =
x5}.This corresponds to the set ∆
′ = {(S,E, I, T,Ch, V ) : S = S
∗, V = V ∗, E/E∗ =
I/I∗ = T/T ∗ = Ch/C
∗
h} ∈ ∆. Hence, the maximum invariant set of (2.1) on the set
∆′ is the singleton {P ∗}. Therefore, by LaSalle’s Invariance principle, the endemic
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Figure 4: Simulation (in MATLAB) of system (2.1), showing the total number of
susceptible, exposed, acutely infected, chronically infected, treated and vaccinated
individuals as a function of time (years) when R0 > 1. Parameter values are given
in Table 2, with ψ = 0.6, ρ = 0, σ = 0, β1 = 0.0009, β2 = 0.0006, and β3 = 0.0001.
The numerical simulation shows that the disease persists when R0 > 1.
equilibrium P ∗ is globally stable in ∆ when ρ = 0 and σ = 0. This result is illustrated
by simulating the model in equation (2.1) using a reasonable set of parameter values
given in Table 2. The plot shows that the disease persists in the population (Fig. 4).
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3 Conclusions
This paper presents a deterministic model for the transmission dynamics of Hepatitis
C virus infection. The formulated model, realistically, allows HCV transmission by
acutely and chronically infected individuals. Most importantly, the model includes a
compartment of vaccinated individuals, and considers the effect of a waning vaccine
on the transfer of individuals from one compartment to another. The model was
rigorously analyzed to gain insights into its qualitative dynamics. We obtained the
following results:
1. The model has a locally stable disease free equilibrium whenever the associated
reproduction number is less than unity.
2. The model exhibits the phenomenon of backward bifurcation, suggesting a case
where stable disease-free equilibrium co-exists with a stable endemic equilib-
rium whenever the basic reproductive number is less than unity.
3. Using an imperfect Hepatitis C vaccine would have no positive epidemiological
impact to reduce disease burden in the community.
4. Using a perfect vaccine can result in effective elimination of HCV infection in
a community, that is, the efficacy of the vaccine should be 100% for complete
removal of the disease.
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